Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04463680 · ClinicalTrials.gov registry record · Phase 4
Rifampin and the Contraceptive Implant
A Phase 4 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
NCT04463680 is a Phase 4 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 24 participants.
The verdict
NCT04463680, a Phase 4 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
Study Summary
It is important for women taking rifampin to be aware if they are at greater risk of an unintended pregnancy while on the implant. An unintended pregnancy has many social, emotional, and financial impacts on women and society. Rifampin is also a Class C medication for pregnancy and could have potential negative effects on a developing fetus. Additionally, women considering rifampin for treatment of LTBI face additional risks with an unintended pregnancy, making the reliability of contraception even more important for these women. The results of this study can directly inform counseling on a national and international basis for women who use the contraceptive implant and are considering their treatment options for LTBI.
Interventions
- DRUG Rifampin 600 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2020-09-23 |
| Est. Completion | 2022-02-22 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04463680
The ClinicalTrials.gov registry entry for NCT04463680 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rifampin 600 MG is the first listed.
NCT04463680 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04463680 about?
NCT04463680 is a clinical study titled "Rifampin and the Contraceptive Implant". It is important for women taking rifampin to be aware if they are at greater risk of an unintended pregnancy while on the implant. An unintended pregnancy has many social, emotional, and financial impacts on women and society. Rifampin is also a Class C medication for pregnancy and could have potent...
What is the current status of trial NCT04463680?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2020-09-23. Estimated completion is 2022-02-22.
What interventions are being tested in trial NCT04463680?
The interventions under investigation include: Rifampin 600 MG (DRUG).
Who is sponsoring clinical trial NCT04463680?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.